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Abstract 
Objectives: The involvement of epigenetics mechanisms in the transcriptional regulation of key 
genes has been investigated in the initiation and progression of neurodegenerative disorders, 
including Parkinson’s disease (PD). Among others, we here focused the attention on the dopamine 
transporter (DAT) gene playing a critical role in maintaining the integrity of dopaminergic neurons.  
Materials and Methods: We performed bisulfite pyrosequencing to examine DNA methylation 
levels of six CpG sites in the 5’-UTR of DAT1 gene in human peripheral blood mononuclear cells 
(PBMCs) obtained from 101 sporadic PD patients and 59 healthy controls.  
Results: We selectively report for CpG5 an increase in DNA methylation levels in PD subjects 
respect to controls, that almost reaches statistical significance (30.06 ± 12.4 vs 26.58 ± 7.6, 
p=0.052). Of interest, a significantly higher methylation at specific CpG sites (ANOVA: p = 0.029) 
was observed in PD subjects with advanced stage of illness. Namely, a multivariate regression 
analysis showed that a higher methylation level at specific CpG sites in the group of PD patients 
was associated with increased methylation at CpG2, CpG3 and with H&Y stage but not with age 
and gender. This regression model explains the 38% of the variance of methylation at CpG5.  
Conclusion: Our results do seem to suggest that the methylation level of CpG5 is different between 
PD patients and controls. Moreover, this methylation level for CpG5 may be associated also with 
the stage of disease. 
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Introduction 
 Parkinson’s disease (PD) is a complex neurodegenerative disorder characterized by impairment of 
dopaminergic (DA) function that leads to the typical clinical motor and non-motor features .1 PD is 
often diagnosed after significant pathology and neuronal cell loss has occurred. The molecular 
mechanisms causing the loss of dopaminergic neurons in the substantia nigra are still unknown. 
Accurate early diagnosis suffers from the lack of reliable biomarkers. 
A key player in DA neurotransmission is the dopamine transporter (DAT), a protein located at the 
nerve terminals within the striatum where modulates the dynamics and the levels of released 
dopamine, by recycling extracellular dopamine back into the pre-synaptic terminal, thus terminating 
its action.2 A dysregulated DA activity may stem from altered release or reuptake and therefore a 
proper regulation of DAT expression is critical to maintain homeostasis in the dopamine system. 
DAT concentration closely relates to striatal dopamine levels.3 In particular, DAT is decreased with 
DA neurodegeneration of nigrostriatal neurons4 and therefore is considered a marker of DA 
terminal integrity, supporting its use as an imaging biomarker for PD.5 Patients, however, are 
already typically symptomatic when these diagnostic neuroimaging techniques are used.6  
The increasing relevance of epigenetic-based regulatory mechanisms encompasses the development 
and progression of many neurodegenerative diseases including PD.7,8 Epigenetic mechanisms 
include any process regulating gene expression without affecting the genome sequence.9 In 
particular, DNA methylation, in which a methyl group is added to the cytosine in CpG sequences, 
may account for underlying mechanisms of gene-environment interaction and their participation in 
the neurological disorders, by modulating genes transcriptional activity.  In most cases, a higher 
methylation leads to a repression of the gene. Altered methylation pattern of several genes have 
been found in both familial and sporadic PD.10-17 Besides, some epigenetic modifications in PD 
were reported to occur early on, before extensive neuronal death has occurred.18 Therefore, research 
on epigenetic variations such as abnormal DNA methylation of specific genes may account for the 
variability in the course of PD and could give insights into the pathogenesis of this disease and 
provide new biomarkers for early diagnosis and therapeutic strategies for PD. 
Furthermore, significant and concordant changes in DNA methylation were found in several genes 
in both peripheral blood mononuclear cells (PBMCs) and brain of PD subjects 19, making PBMCs a 
valid source for brain methylation studies involved in disease pathogenesis. In particular, it has 
recently been described a positive correlation of DAT1 promoter methylation levels between 
PBMCs and substantia nigra in both postmortem ADHD and control subjects.20 
Clinical and experimental studies seem to support the evidence that synaptic dysfunction may 
represent an early stage of DA neurons degeneration of the substantia nigra pars compacta.21,22 
Considering the prominent role of DA system dysregulation in PD, the epigenetic derangement of 
the dopamine metabolism determinants, such as of the DAT1 gene, coding for human DAT, 
deserves a peculiar attention. It has been shown that DAT1 gene expression is very susceptible to 
epigenetic modifications.23 Moreover, several studies conducted in vitro 24 and in MPTP-treated 
mice at modelling preclinical and early clinical stages of PD 25,  have shown in the striatum a 
reduction in both DAT protein expression and content, while a trend for reduced expression of 
DAT1 gene was also detected in isolated DA neurons from the substantia nigra of idiopathic PD 
patients.26  
Based on the above premises, the present cross-sectional study aimed to investigate the methylation 
level of DAT1 gene in peripheral cells of PD patients and control subjects, as well as its correlation 
with demographic and clinical characteristics of PD patients. We here analyzed the DNA 
methylation level of specific CpG sites located in the 5’-untranslated region (5’-UTR) of the DAT1 
gene. Several studies demonstrated a closer correlation between DNA methylation downstream of 
the transcriptional starting site (TSS) and the repression of gene transcription than methylation 
upstream of TSS, i.e., in the promoter region. 27, 28 In a previous study, we also showed a decrease in 
the DNA methylation levels in the same 6 CpG sites of the 5’UTR DAT1 region here analyzed in 
buccal mucosa cells of ADHD subjects, respect to controls, which correlated with an increase of 
serum aAbs. 29  
 
Materials and Methods  
Samples.  The study group consisted of 101 unrelated sporadic PD outpatients, consecutively 
recruited from June 2017 to July 2018 at the Department of Human Neuroscience, Sapienza 
University of Rome and fulfilled the UK Brain Bank criteria for PD.30 Exclusion criteria included: 
signs of atypical parkinsonism; history of neurological diseases other than idiopathic PD; diagnosis 
of mental retardation or dementia (Mini-Mental State Examination score <23.8); presence of major 
non stabilized medical illnesses (i.e. non stabilized diabetes, obstructive pulmonary disease or 
asthma, hematologic/oncologic disorders, vitamin B12 or folate deficiency, pernicious anemia, 
clinically significant and unstable active gastrointestinal, renal, hepatic, endocrine or cardiovascular 
disorders); brain tumors and known or suspected history of alcoholism, drug dependence and abuse, 
head trauma and mental disorders according to the DSM-IV-TR criteria. The variables collected 
included: demographic data, disease duration, total levodopa equivalent dose (LEDD) calculated 
according to Tomlinson 31, Hoehn & Yahr staging (H&Y) and Unified Parkinson’s Disease Rating 
Scale-subset III (UPDRS III) at the time of last visit.   
The control group comprised 59 subjects, recruited among unrelated patients’ carers healthy 
volunteers (n=33) and blood donors (n=26). The exclusion criteria were alcohol and substance abuse, 
neurological disorders, family history of movement disorders. Subjects suffering from metabolic 
disorders, severe hypertension or systemic autoimmune diseases were also excluded. All participants 
provided written informed consent and the study protocol was approved by the local ethics committee. 
Demographic and clinical characteristics for the study samples are shown in Table 1. 
 
Analysis of DNA methylation by bisulfite pyrosequencing. Methylation status of the DAT1 5′-UTR 
sequence was determined using pyrosequencing of bisulfite-converted genomic DNA isolated by 
standard method from blood cells. After DNA extraction, 0.5 μg of DNA from each sample underwent 
bisulfite modification to convert unmethylated cytosine residues to uracil, using a DNA methylation 
kit (Zymo Research, Orange, CA, USA). Bisulfite-treated DNA was amplified by the PyroMark PCR 
Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The schematic 
representation of CpG island in DAT1 5′-UTR region is illustrated in Figure 1. Details on the 
sequence and the pyrosequencing assay (PM00022064) are available on the Qiagen web site 
(www.qiagen.com). PCR conditions were: 95 °C for 15 min, followed by 45 cycles of 94 °C for 30 
s, 56 °C for 30 s, 72 °C for 30 s, and, finally, 72 °C for 10 min. PCR products were verified by agarose 
gel electrophoresis. Pyrosequencing methylation analysis was conducted using the PyroMark Q24 
(Qiagen, Hilden, Germany). The level of methylation for each patient and control was analysed using 
PyroMark Q24 Software (Qiagen, Hilden, Germany), which calculates the methylation percentage 
(mC/(mC + C)) for each CpG site, allowing quantitative comparisons (mC is methylated cytosine, C 
is unmethylated cytosine). Two standard human DNA samples, fully methylated (100%) and 
unmethylated DNA (0%) were purchased from Zymo (Zymo Research; Irvine, CA, USA) and used, 
respectively, as positive and negative methylation control. They were bisulfite-converted and were 
run along with the experimental samples. 
 
Statistical analysis. Methylation percentages for PD patients and controls were expressed as mean ± 
SD. Average methylation percentages for the DAT1 5′-UTR were calculated by averaging 
methylation level of the 6 CpG sites analysed. Student’s t tests were used to compare differences in 
the mean values of continuous variables between PD and control subjects, and ANOVA was used for 
the comparison between four groups (PD H&Y stage I, II, III and controls). Correlations analyses of 
CpGs methylation were performed for clinical features in PD population by means of Pearson’s index. 
Subsequently, the analysis was implemented with a multiple linear regression to assess the association 
between degree of methylation and clinical features identified as variables statistically relevant to 
univariate analysis. All statistical analyses were performed using the SPSS software (version 25.0). 
Significance levels were established at a value of p < 0.05. We did not test for multiple corrections 
for the exploratory character of this study. 
 
 
Results 
 
The characteristics of the patients and controls enrolled in the present study are shown in Table 1. 
No statistically significant differences were found between patients and controls for age and gender 
(Table 1). Pyrosequencing method was utilized to quantify methylation levels at 6 CpG sites in the 
5’-UTR of the DAT1 gene (Figure 1). No statistically significant differences were found between 
PD patients and controls in terms of total methylation value, as well as at each CpG site, except for 
CpG5 that showed an increased methylation level in PD subjects respect to controls (30.06 ± 12.4 
vs 26.58 ± 7.6, p=0.052) (Table 1). However, as DNA methylation levels can be impacted by 
several confounding factors32, 33, we analysed the methylation of the 6 CpG sites after stratification 
based on age, gender as well as disease severity of PD patients, according to H&Y stage and 
compared with healthy subjects (Table 2). No differences between male and females were observed 
according to disease severity.  The age was statistically significant when we consider the 
comparison between four groups (H&Y I, II, III and controls) (p=0.001) (Table 2). At ANOVA 
analyses the CpG sites 2, 3, 5 and total CpGs methylation values were statistically significant 
different between the four groups studied (H&Y I, II, III and controls), with a p value of 0.05, 
0.004, 0.029 and 0.048 respectively.  
A correlation analysis showed a statistically significant association between age and sites 1, 2, 3, 5, 
6 and total CpGs, with p value of 0.08, 0.002, 0.01, 0.012, 0.045 and 0.001 respectively. 
Furthermore, increased methylation at CpG5 correlates with increased methylation level of all 
studied sites. Other PD-related phenotypes analysed, such as age at PD onset (p=0.225), UPDRS III 
score (p=0.236), LEDD (p=0.93) and PD clinical subtypes (p=0.45) were found not significantly 
correlated to the methylation of the CpG island we studied. 
Since CpG5 was the only statistically different variable between PDs and controls (Table 1), it was 
considered as the discriminant variable in this study. Moreover, the ANOVA analyses show that 
CpG2 and 3 were statistically significant in accordance to stage of the disease (Table 2) and were 
statistically significant correlated a the CpG5 (p= 0.001 for both correlations). 
A multivariate regression analysis (methylation at CpG5 as dependent variable) considering age, 
gender, H&Y stage, CpG2 and 3 methylation level, was performed in order to determine the 
contribution of these variables to the variance of methylation at CpG5. The regression model shows 
that of all the included variables only DAT1 hypermethylation at CpG2 (p= 0.001), CpG3 (p= 
0.002) and H&Y stage (p=0.011), are factors significantly associated with methylation at CpG5. 
The overall regression model has a R2 value of 38% (Table 3). Moreover, the regression 
multivariate analysis showed that the observed differences in methylation level were independent of 
age (p=0.389) and gender (p=0.88) (Table 3).  
 
 
 
 
Discussion  
 
Recent studies of genome-wide methylation have highlighted the presence of differentially 
methylated regions spread across the genome in PD subjects respect to controls.19, 34 However, the 
role of DNA methylation and its link to sporadic PD is not completely defined and clearly 
characterized.  
Herein we investigated the methylation status of a CpG island in the 5’-UTR of the DAT1 gene in 
sporadic PD and control subjects, considering the key role played by the dopamine transporter in 
maintaining the integrity of DA neurons. By comparing the methylation level between the two 
groups, we observed an increased methylation at CpG site5 in PD that almost reaches statistical 
significance. We further analyse this result considering the contribution of several PD confounding 
factors. Most important findings from the present study show significant correlation between the 
increased methylation of CpG5 and that of all other CpGs in the island analysed. Moreover, we 
observed higher levels of methylation at specific CpGs of PD patients with advanced stage of 
disease respect to controls and PD patients with mild disease. The increased methylation according 
to the clinical variables that mainly express PD severity, seem to suggest that dynamic changes of 
methylation patterns may emerge during disease progression. The role of DNA methylation and its 
link to PD progression is currently unclear and remain poorly characterized. In the brain, epigenetic 
mechanisms dynamically regulate gene expression in response to environmental influences 
throughout the lifespan, enabling adaptive plasticity. The role of DNA methylation as a possible 
mediator of environmental inputs that drive PD development and/or progression is just starting to 
be explored.  
Under normal physiological conditions, increased dopamine release rapidly upregulates DAT 
membrane expression. It can be hypothesized that with DA depletion of nigrostriatal neurons, 
increased during PD progression, a modulation of DAT1 gene expression, which leads to a 
reduction in protein levels could occur in the remaining neurons, in order to have more stable level 
of dopamine in the synaptic gap.  
Gene expression studies showed a trend for reduced expression of DAT by qRT-PCR in PD 
dopamine neurons.26 Although the effects of DNA methylation on gene expression are complex, 
heavily methylated genes are usually less active (gene expression turned off) by preventing the 
formation of transcriptional machinery at the target sites. 
DNA hyper-methylation could well be the mechanism responsible for the reduction of DAT 
expression in the pre-synaptic membrane. 
Furthermore, as the increased uptake of dopamine or other toxins via DAT is the key component of 
dopamine-induced neurotoxicity in the DA neurons, an inhibition or reduction of its entry into the 
cell, could represent an extreme attempt against neurodegeneration.  
Cytosine methylation of CpG sequences might regulates gene expression by affecting the ability of 
transcription factors to access and bind specific regions in promoter sequence.35 In particular, CpG 
sites 5 and 6 in the 5’-UTR analysed, represent a CGCG-core motif that is a putative transcription 
factor binding site for members of a family of calmodulin-binding transcription activators 
(CAMTAs), recognized as integrators of stress responses.36, 37 In neuroblastoma cells, it has been 
shown that CAMTA1 primarily regulates genes involved in neuronal function and differentiation.38 
Such binding to the DNA could be inhibited by CpG methylation of the CGCG motif preventing 
gene expression. Other factors may have, indeed, affected the levels of DNA methylation of 5’-
UTR of DAT1 gene, including, individual differences in DAT expression among PD subjects. 
Our study presents some limitations. Given the concern that the small sample size of the population 
examined cannot allow conclusive evaluations, these results support the hypothesis that epigenetic 
modifications in the DAT1 gene could partake in PD progression. However, the potential of DAT1 
gene methylation as a biomarker in PD, in particular during disease progression, warrants further 
investigations in an independent sample including a larger group of PD patients as well as DAT1 
gene expression evaluation. Furthermore, a longitudinal DAT1 methylation analysis of PD patients, 
integrated with DAT1 gene expression, together with functional neuroimaging evaluation, could 
provide insights into the biological implication of DAT1 methylation and PD.  
Notwithstanding these limitations, in our knowledge, this is the first study to explore the association 
between 5’-UTR DAT1 epigenetic modifications and PD. The findings of this study may be an 
additional step toward understanding the role of specific epigenetic modifications underlying PD 
pathogenesis. 
Conflict of Interest 
The authors have no conflict of interest to declare. 
References 
1. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015;386:896–912. 
 
2. Giros B, Caron MG. Molecular characterization of the dopamine transporter. Trends Pharmacol 
Sci 1993;14:43–49. 
 
3. Mozley PD, Schneider JS, Acton PD, et al. Binding of [99mTc]TRODAT-1 to dopamine 
transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 
2000;41:584-9.  
 
4. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of 
patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J 
Med 1988;318(14):876-80. 
 
5. Brooks DJ. Molecular imaging of dopamine transporters. Ageing Res Rev 2016;30:114-21.  
 
6. Seifert KD, Wiener JI. The impact of DaTscan on the diagnosis and management of movement 
disorders: A retrospective study. Am J Neurodegener Dis 2013;2(1):29-34. 
 
7. Wullner U, Kaut O, deBoni L, Piston D, Schmitt I. DNA methylation in Parkinson’s 
disease. J Neurochem 2016;139(suppl 1):108–120. 
 
8. Miranda-Morales E, Meier K, Sandoval-Carrillo A, Salas-Pacheco J, Vazquez-Cardenas P, Arias-
Carrion O. Implications of DNA methylation in Parkinson’s disease. Front Mol Neurosci 
2017;10:225.  
 
9. Dupont C, Armant R, Brenner AC. Epigenetics: definition, mechanisms and clinical perspective. 
Stem Cell Res Ther 2016;27:351–7. 
 
10. Ai SX, Xu Q, Hu YC, et al. Hypomethylation of SNCA in blood of patients with sporadic 
Parkinson’s disease. J Neurol Sci 2014;337:123-128. 
 
11. Schmitt I, Kaut O, Khazneh H, et al. L-dopa increases synuclein DNA methylation in 
Parkinson’s disease patients in vivo and in vitro. Mov Disord 2015;30:1794–801. 
 
12. De Mena L, Cardo LF, Coto E, Alvarez V. No differential DNA methylation of PARK2 in brain 
of Parkinson’s disease patients and healthy controls. Mov Disord 2013;28(14):2032–3.  
 
13. Coupland KG, Mellick GD, Silburn PA, et al. DNA methylation of the MAPT gene in 
Parkinson’s disease cohorts and modulation by vitamin E in vitro. Mov Disord 2014;2913:1606–14. 
 
14. Cai Y, Liu S, Sothern RB, Xu S, Chan P. Expression of clock genes Per1 and Bmal1 in total 
leukocytes in health and Parkinson’s disease. Eur J Neurol 2010; 17(4):550–4.  
 
15. Su X, Chu Y, Kordower JH, et al. PGC-1α promoter methylation in Parkinson’s disease. PLoS 
One 2015;10 (8), e0134087. 
 
16. Moore K, McKnight AJ, Craig D, et al. Epigenome wide association study for Parkinson’s 
disease. Neuromolecular Med 2014;16(4):845–55. 
 
17. Chuang YH, Paul KC, Bronstein JM, et al. Parkinson’s disease is associated with DNA 
methylation levels in human blood and saliva. Genome Med 2017;9(1):76. 
 
18. Calligaris R, Banica M, Roncaglia P, et al. Blood transcriptomics of drug-naïve sporadic 
Parkinson’s disease patients. BMC Genomics 2015;16,876. 
 
19. Masliah E, Dumaop W, Galasko D, Desplats P. Distinctive patterns of DNA methylation 
associated with Parkinson disease: identification of concordant epigenetic changes in brain and 
peripheral blood leukocytes. Epigenetics 2013;8:1030–8. 
 
20. Wiers CE, Loholl FW, Lee J, et al. Methylation of the dopamine transporter gene in blood is 
associated with striatal dopamine transporter availability in ADHD: a preliminary study. Eur J 
Neurosci 2018;48(3):1884-95. 
 
21. Schirinzi T, Madeo G, Martella G, et al. Early synaptic dysfunction in Parkinson’s disease: 
insights from animal models. Mov Disord 2016;31:802–13. 
 
22. Xylaki M, Atzler B, Fleming Outeiro T. Epigenetics of the Synapse in Neurodegeneration. Curr 
Neurol Neurosci Rep 2019;19(10),72. 
 
23. Shumay E, Fowler JS, Volkow ND. Genomic features of the human dopamine transporter gene 
and its potential epigenetic states: implications for phenotypic diversity. PLoS One 2010; 
5(6):e11067.  
 
24. Green AL, Hossain MM, Tee SC, Zarbl H, Guo GL, Richardson RJ. Epigenetic Regulation of 
Dopamine Transporter mRNA Expression in Human Neuroblastoma Cells. Neurochem Res 2015; 
40(7):1372–8.  
 
25. Mingazov ER, Khakimova GR, Kozina EA, et al. MPTP Mouse Model of Preclinical and 
Clinical Parkinson's Disease as an Instrument for Translational Medicine. Mol Neurobiol 
2018;55(4):2991-3006.  
 
26. Simunovic F, Yi M, Wang Y, et al. Gene expression profiling of substantia nigra dopamine 
neurons: further insights into Parkinson’s disease pathology. Brain 2009;132(7):1795-809.  
 
27. Brenet F, Moh M, Funk P, Feierstein E, Vitale AJ, Socci ND, et al. DNA methylation of the 
first exon is tightly linked to trascriptional silencing. PLoS ONE 2011;6:e14524. 
 
28) Sakamoto A, Akiyama Y, Shimada S, Zhu WG, Yuasa Y, Tanaka S. DNA methylation in the 
exon 1 region and complex regulation of twist1 expression in gastric cancer cells. PLoS ONE 2015; 
10(12):e0145630. 
 
29. Adriani W, Romano E, Pucci M, et al. Potential for diagnosis versus therapy monitoring of 
attention deficit hyperactivity disorder: a new epigenetic biomarker interacting with both genotype 
and auto-immunity. Eur Child Adolesc Psychiatry 2018;27(2):241-252.  
 
30. Hughes AJ, Daniel SE, Kilford L, Lees A J. Accuracy of clinical diagnosis of idiopathic 
Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 
1992;55:181–4.  
 
31. Tomlinson C L, Stowe R, Patel S, Rick C, Gray R, Clark, C E. Systematic review of levodopa 
dose equivalency reporting in Parkinson’s disease. Mov Disord 2010;25:2649–53.  
 
32. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of 
monozygotic twins. Proc Natl Acad Sci U S A 2005;102(30):10604-9. 
 
33. El-Maarri O, Becker T, Junen J, et al. Gender specific differences in levels of DNA methylation 
at selected loci from human total blood: a tendency toward higher methylation levels in males. Hum 
Genet 2007;122:505-14. 
 
34. Young JI, Sivasankaran S, Wang L, et al. Genome-wide brain DNA methylation analysis 
suggests epigenetic reprogramming in Parkinson’s disease. Neurol Genet 2019;5(4):e342. 
 
35. Domcke S, Bardet AF, Ginno PA, Hartl D, Burger L, and Schubeler D. Competition between 
DNA methylation and transcription factors determines binding of NRF1. Nature 2015;528: 575–9. 
 
36. Shen C, Yang Y, Du L, Wang H. Calmodulin-binding transcription activators and perspectives 
for applications in biotechnology. Appl Microbiol Biotechnol 2015;99:10379-85.  
 
37. Mollet IG, Malm HA, Wendt A, Orho-Melander M, Eliasson L. Integrator of Stress Responses 
Calmodulin Binding Transcription Activator 1 (Camta1) Regulates miR-212/miR-132 Expression 
and Insulin Secretion. J Biol Chem 2016;291:18440-52.  
 
38. Henrich KO, Bauer T, Schulte J, et al. CAMTA1, a 1p36 tumor suppressor candidate, inhibits 
growth and activates differentiation programs in neuroblastoma cells. Cancer Res 2011;71:3142–
51. 
 
 
 
  
 Table 1. Demographic, clinical features and DNA methylation at cytosine-guanine (CpG) sites 
of the 5’-UTR of DAT1 gene of studied populations. 
 
 Patients (n=101) Controls (n=59) p value 
Age (yrs, mean±SD) 68.5±8.2 70.15±6.64 0.18 
Gender M/F 64% (65)/36% (36) 51% (30)/49% (29) 0.062 
Age at onset (yrs, mean±SD) 61.2±11   
UPDRS III score 15.05±6.9   
H&Y (mean±SD) 1.91±0.7   
LEDD at last visit  
(mg/die, mean±SD) 
500±368   
Clinical subtype NTD/TD 58% (59)/42% (42)   
5’-UTR DAT1 methylation % 
            CpG site 1 
                               
12.56±4.0                         
                               
13.02±3.7 
 
0.47 
            CpG site 2 11.89±4.9 11.78±2.9 0.85 
            CpG site 3 15.77±4.9 15.04±3.3 0.30 
            CpG site 5 30.06±12.4 26.58±7.6 0.052 
            CpG site 6 5.67±1.5 5.60±1.6 0.77 
            CpG site 7 11.86±4.5 11.99±3.1 0.85 
            Total CpGs 14.65±4.3 14.05±2.8 0.34 
Data are expressed as mean ± standard deviation (range). UPDRS III, Unified Parkinson's Disease Rating Scale part III; 
H&Y, Hohen &Yahr scale; LEDD, levodopa equivalent daily dose. NTD, non-tremor dominant; TD, Tremor dominant 
clinical subtypes. 
 
Table 2. A comparison between PD patients and controls in according to severity of disease  
 PD  Controls (n=59) p value 
 H&Ystage I 
(n=30) 
H&Ystage II 
(n=49) 
H&Ystage III 
(n=22) 
  
Age 
(yrs,mean±SD) 
 
64.27±8.5 
 
68.87±7.05 
 
73.68±7.2 
 
70.15±6.64 
 
0.001 
Gender M/F 21/9 31/18 13/9 30/29 0.3 
5’-UTR DAT1 
methylation%  
        CpG site 1 
                      
                   
12.71± 3.3                               
                                                                  
 
11.79±3.2 
                                       
 
   14.05±5.9 
 
13.02±3.7 
 
 
0.13        
        CpG site 2 11.39±3.9 11.21±3.9    14.08±7.1  11.78±2.9 0.055 
        CpG site 3 15.87±4.1 14.53±3.5    18.40±7.2  15.04±3.3 0.004 
        CpG site 5   32.80±16.8 27.53±8.8 31.98±11.5  26.58±7.6 0.029 
        CpG site 6      5.73±1.3   5.38±1.1 6.24±2.2    5.60±1.6 0.16       
        CpG site 7 11.97±4.5 11.59±4.7    12.31±4.4 11.99±3.1 0.91        
        Total CpGs 15.08±4.5 13.69±3.5    16.18±5.1 14.05±2.8 0.048 
p-Values for continuous variables are from one-way analysis of variance (ANOVA).  
 
 
  
Table 3 A multivariate regression model considering CpG 5 as dependent variable 
 
Model 
Not-standardized 
coefficients 
Standardized 
coefficients 
t Sign. B Standard error Beta 
1 (Costant) 5,644 6,839  0,825 0,411 
Age 0,090 0,104 0,063 0,870 0,386 
Gender -0,210 1,507 -0,009 -0,139 0,889 
H&Y -1,722 0,665 -0,178 -2,591 0,011 
CpG site 3 0,642 0,207 0,255 3,097 0,002 
CpG site 2 1,012 0,207 0,394 4,896 0,001 
 
Dependent variable: CpG site 5. The overall regression model has a R2 value of 
38%. 
 
Figure 1. Schematic representation of the CpG island at the 5’-UTR DAT1 region analyzed. Bold 
text indicates the CpG sites. 
